158 related articles for article (PubMed ID: 3204010)
21. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
[TBL] [Abstract][Full Text] [Related]
22. Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
Filella X; Molina R; Mengual PJ; Jo J; Ballesta AM
J Nucl Biol Med (1991); 1991; 35(3):158-61. PubMed ID: 1816871
[TBL] [Abstract][Full Text] [Related]
23. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
[TBL] [Abstract][Full Text] [Related]
24. The use of CA15.3 as a serum tumour marker in breast carcinoma.
Duncan JL; Price A; Rogers K
Eur J Surg Oncol; 1991 Feb; 17(1):16-9. PubMed ID: 1995353
[TBL] [Abstract][Full Text] [Related]
25. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
26. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
[TBL] [Abstract][Full Text] [Related]
27. [CA15-3 tumor marker in early detection of breast cancer].
Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
[TBL] [Abstract][Full Text] [Related]
28. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
Gebauer G; Müller-Ruchholtz W
Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706
[TBL] [Abstract][Full Text] [Related]
29. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
Yoshimoto M
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2277-83. PubMed ID: 2241194
[TBL] [Abstract][Full Text] [Related]
30. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
31. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
32. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
33. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
34. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
[TBL] [Abstract][Full Text] [Related]
35. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
36. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
[TBL] [Abstract][Full Text] [Related]
37. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
38. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
39. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]